Use the labels in the right column to find what you want. Or you can go thru them one by one, there are only 29,372 posts. Searching is done in the search box in upper left corner. I blog on anything to do with stroke. DO NOT DO ANYTHING SUGGESTED HERE AS I AM NOT MEDICALLY TRAINED, YOUR DOCTOR IS, LISTEN TO THEM. BUT I BET THEY DON'T KNOW HOW TO GET YOU 100% RECOVERED. I DON'T EITHER BUT HAVE PLENTY OF QUESTIONS FOR YOUR DOCTOR TO ANSWER.
Saturday, January 25, 2020
Neuroplasticity and cognitive benefits associated with chronic intranasal oxytocin administration in aging
Would this help stroke survivors? We'll never know since we have NO STROKE LEADERSHIP and NO STROKE STRATEGY.
Stockholm University, Faculty of Social Sciences, Department of Psychology, Biological psychology.
Lin, Tian
Lussier, Desiree
Show others and affiliations
2019 (English)Conference paper, Oral presentation only (Other academic)
Abstract [en]
Oxytocin (OT) is a
crucial chemical modulator of social behavior, and intranasal OT
administration has potential as treatment for social deficits.
Considerably less is known about OT’s effects on non-social cognition, a
functional domain of particular relevance in aging. Brain mechanisms
underlying OT’s benefits are not well understood but recent animal work
suggests that repeated OT administration induces brain changes. To test
this neuroplastic role of OT on the human brain and its potential for
cognitive improvement in aging, we conducted a randomized double-blind
study in older men (> 56 years), with 34 participants
self-administering either 24 IUs OT or placebo (P) twice daily. Before
and after 4-weeks intranasal administration, participants underwent MRI
and processing speed assessment. Using voxel-based morphometry, gray
matter (GM) volume was measured on T1-weighted anatomical images. Age,
education, physical health, and image quality served as covariates and
family-wise error rate determined statistical significance in regions of
interest. Analyses were performed without awareness of the assigned
treatment labels. Significant interactions between treatment (OT vs. P)
and time (pre- vs. post-intervention) on GM volume for left amygdala,
hippocampus, and putamen suggested increased regional GM volume
following OT but not P. Further, OT-induced enlargement in putamen was
associated with improved processing speed, while there was no
brain−behavior correlation in the P group. These findings support the
notion that amygdala, hippocampus, and putamen are key targets of OT’s
neuroplastic potential on the human brain and chronic OT administration
may constitute a potential treatment in counteracting cognitive decline
in aging.
No comments:
Post a Comment